Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
TRIUMPH-1's 28.3% and TRIUMPH-4's 28.7% remain the highest results in the program both trials enrolled patients without diabetes, unlike TRIUMPH-2 (which specifically included diabetes) and TRIUMPH-3 (which specifically included cardiovascular disease)
You don't have to figure this out alone: our medical team matches the medication to you, and your DNA can tell us even more about why one is working
Serrano said these barriers lead people to consider using off-brand versions of the medications
Adherence and persistence research abstract Learn more about the methodology of Primes research study, Year-Two Real-World Analysis of Glucagon-Like Peptide-1 Agonist (GLP-1) Obesity Treatment Adherence and Persistency. Cost-of-care data Individuals without diabetes who started a GLP-1 medication for obesity experienced an average of $4,206 higher cost of care in their second year compared to similar members who did not take a GLP-1 drug for obesity
